Since Gamunex is, as you noted, Talecris's biggest product, and it is facing a future competition from Baxter's IGIV, I was thinking, maybe this puts extra pressure on Talecris to move on with its inhaled AAT program. Talecris like Kamada also got an orphan drug designation and if approved first, they may block Kamada's inhaled AAT.
Market Data 
Markets 
AI
